Starling Oncology, Inc. STLN

About Starling Oncology, Inc. (STLN): stock profile, AI score and financials

Starling Oncology, Inc. (STLN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STLN at 45.0/100 on a composite quality score built from its SEC filings, placing it at rank #1,903 of 2,925 stocks — the bottom half of the AI-ranked universe. STLN scores in the top quartile across revenue growth (86.4). Areas of concern include balance sheet strength (10.5) and free cash flow (26.5), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), Starling Oncology, Inc. reports quarterly revenue of $161.3M, net income of $-9.8M, an operating margin of -2.9%. Top institutional holders of STLN by reported 13-F value include BlackRock, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. STLN trades on the Nasdaq exchange and files with the SEC under CIK 1799191. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STLN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Starling Oncology, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1799191 →